Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc by (c) Muñoz Cano et al., 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/151862

Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

Platelet-activating factor (PAF) is a lipid mediator involved in several allergic reactions. It is released from multiple cells of the immune system, such as eosinophils, neutrophils, and mast cells, and also exerts its effect on most of them upon specific binding to its receptor, becoming a pleiotropic mediator. PAF is considered a potential relevant mediator in allergic rhinitis, with a key role in nasal congestion and rhinorrhoea due to its effect on vascular permeability. Interestingly, despite its potential relevance as a therapeutic target, no specific PAF inhibitors have been studied in humans. However, rupatadine, a second-generation antihistamine with dual antihistamine and anti-PAF effects has shown promising results by both blocking nasal symptoms and inhibiting mast cell activation induced by PAF, in comparison to antihistamine receptor drugs. In conclusion, the inhibition of PAF may be an interesting approach in the treatment of allergic rhinitis as part of a global strategy directed at blocking as many relevant inflammatory mediators as possible.

Matèries (anglès)

Citació

Citació

MUÑOZ-CANO, Rosa, CASAS SAUCEDO, Rocio, VALERO, Antonio, BOBOLEA, Irina, RIBÓ GONZÁLEZ, Paula, MULLOL I MIRET, Joaquim. Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications. _Journal of Clinical Medicine_. 2019. Vol. 8, núm. 9. [consulta: 11 de abril de 2026]. [Disponible a: https://hdl.handle.net/2445/151862]

Exportar metadades

JSON - METS

Compartir registre